NEURELIS
Neurelis is a specialty pharmaceutical company, licenses, develops, and commercializes product candidates for epilepsy and the broader central nervous system (CNS) market. It provides a differentiated approach to target unmet medical needs. Their application of novel technologies is designed to enhance the therapeutic benefit and patient care. The company was incorporated in 2007 and is based in Encinitas, California.
NEURELIS
Industry:
Biotechnology Health Care Medical Pharmaceutical
Founded:
2007-01-01
Address:
Encinitas, California, United States
Country:
United States
Website Url:
http://www.neurelis.com
Total Employee:
101+
Status:
Active
Contact:
858-251-2100
Email Addresses:
[email protected]
Total Funding:
206.08 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Google Tag Manager Google Universal Analytics Apache Euro IPv6 Google Maps
Similar Organizations
Salix Pharmaceuticals
Salix Pharmaceuticals is a specialty pharmaceutical company focused on the prevention and treatment of gastrointestinal disorders.
Current Advisors List
Current Employees Featured
Founder
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2018-12-03 | Aegis Therapeutics | Aegis Therapeutics acquired by Neurelis | N/A |
Investors List
Philos & Partners
Philos & Partners investment in Series D - Neurelis
LYZZ Capital
LYZZ Capital investment in Series D - Neurelis
Decheng Capital
Decheng Capital investment in Series D - Neurelis
Cormorant Asset Management
Cormorant Asset Management investment in Series D - Neurelis
HBM Healthcare Investments AG
HBM Healthcare Investments AG investment in Series D - Neurelis
HBM Healthcare Investments AG
HBM Healthcare Investments AG investment in Series C - Neurelis
HBM Healthcare Investments AG
HBM Healthcare Investments AG investment in Series B - Neurelis
LYZZ Capital
LYZZ Capital investment in Series B - Neurelis
LYZZ Capital
LYZZ Capital investment in Series A - Neurelis
Key Employee Changes
| Date | New article |
|---|---|
| 2021-10-18 | Neurelis Announces Addition of Brittany Bradrick as CFO and Expansion of Leadership Team and Board of Directors |
Official Site Inspections
http://www.neurelis.com Semrush global rank: 1.08 M Semrush visits lastest month: 30.74 K
- Host name: ec2-3-222-169-180.compute-1.amazonaws.com
- IP address: 3.222.169.180
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Neurelis"
Neurelis®: Helping More People Define Their Neu Normal
Learn about Neurelis®, a neuroscience-based pharmaceutical company developing life-changing treatments that empower patients and HCPs to define their own journey.See details»
SUPPORT TAILORED TO YOUR INDIVIDUAL NEEDS - Neurelis
Neurelis, Inc.: Leadership in Pharmaceuticals
He co-founded Neurelis in 2007, serving as CEO and President, and has raised over $300M in funding to progress the company to a fully integrated organization, from early-stage …See details»
Neurelis - Crunchbase Company Profile & Funding
Neurelis is a specialty pharmaceutical company, licenses, develops, and commercializes product candidates for epilepsy and the broader central nervous system (CNS) market. It provides a differentiated approach to target unmet …See details»
Neurelis, Inc. - LinkedIn
Neurelis, Inc., is dedicated to innovating life-changing therapeutics that help people with neurological conditions gain greater control over their journeys. Engaged, creative, and strategic...See details»
Neurelis Medical Affairs Resource Center
Explore Neurelis Medical Affairs Resource Page for quick access to scientific, disease state, and grant information in one place. Stay informed effortlessly.See details»
Craig C. Chambliss - President & CEO, Co-Founder at Neurelis
Craig Chambliss has 30 years invested in the biopharma and drug delivery arenas, with primary focus on rare diseases of the central nervous system (CNS) and epilepsy, in particular.See details»
Neurelis Inc. - Child Neurology Society
Bringing CNS Members Together to Make Children’s Lives Better. CONNECTING TO... Colleagues. Network; CNS Annual Meeting; Latest News; CNS CalendarSee details»
NEURELIS STRENGTHENS LEADERSHIP TO FURTHER ENHANCE …
Oct 6, 2022 · Neurelis' VALTOCO® (diazepam nasal spray) CIV, a nasal spray for seizure clusters, has transformed from the newest entrant to the clear leader among all approved …See details»
About Neurelis®: Learn About Our Normal in …
Neurelis® is a neuroscience-based specialty pharmaceutical company providing innovative approaches to target unmet medical needs. Learn about the company here.See details»
Neurelis Company Profile 2024: Valuation, Funding
Operator of a neuroscience company intended to target unmet medical needs in epilepsy and orphan CNS (central nervous system).See details»
Innovation in Precision Therapies for CNS ... - Biotech2050 Podcast
Mar 6, 2024 · In this episode of Biotech2050, host Alok Tayi engages in a profound conversation with Craig Chambliss, CEO and co-founder of Neurellis, delving into their strategic …See details»
Neurelis - Overview, News & Similar companies | ZoomInfo.com
Nov 27, 2023 · Neurelis is changing the way central nervous system (CNS) disorders are treated. In 2007, a small group of individuals who were passionate about helping patients started …See details»
Welcome to myNEURELIS® | Supporting Patients & Care Partners
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. How should I use VALTOCO? Read the …See details»
Neurelis® Careers | View Current Opportunities
Neurelis is changing the way silent chronic/acute central nervous system (CNS) disorders are treated. See current opportunities to join the Neurelis family.See details»
Neurelis to Host Virtual Pipeline Update to Discuss ... - BioSpace
SAN DIEGO, Feb. 26, 2024 /PRNewswire/ -- Neurelis, Inc. today announced it will host an investor call to highlight updates on two of its neuroscience product development candidates, …See details»
Neurelis to Host Virtual Pipeline Update to Discuss Advancements ...
SAN DIEGO, Feb. 26, 2024 /PRNewswire/ -- Neurelis, Inc., today announced it will host an investor call to highlight updates on two of its neuroscience product development candidates, …See details»
Neurelis, Inc. Company Profile | San Diego, CA | Competitors ...
Find company research, competitor information, contact details & financial data for Neurelis, Inc. of San Diego, CA. Get the latest business insights from Dun & Bradstreet.See details»
NEURELIS STRENGTHENS LEADERSHIP TO FURTHER ENHANCE …
Oct 7, 2022 · Neurelis’ VALTOCO ® (diazepam nasal spray) CIV, a nasal spray for seizure clusters, has transformed from the newest entrant to the clear leader among all approved …See details»
Neurelis - VentureRadar
Website: http://www.neurelis.com. Develops and commercializes therapeutics for epilepsy and orphan neurologic disorders, addressing high unmet medical needs in neuroscience. …See details»